Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study.

@article{Oberhoff1998RecombinantHE,
  title={Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study.},
  author={Carsten Oberhoff and Bruno Neri and Dino Amadori and K U Petry and Teresa Gamucci and Udo Rebmann and Mohammad Resa Nowrousian and Rudolf Voigtmann and Silvio Monfardini and Jean Pierre Armand and Richard Herrmann and J Netter-Pinon and Nicole Tubiana-Mathieu and Heinz Zwierzina},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1998},
  volume={9 3},
  pages={
          255-60
        }
}
BACKGROUND Anemia is a common side effect of anticancer chemotherapy. Blood transfusion, previously the only available treatment for chemotherapy-induced anemia, may result in some clinical or subclinical adverse effects in the recipients. Recombinant human erythropoietin (rhEPO) provides a new treatment modality for chemotherapy-induced anemia. PATIENTS AND METHODS To evaluate the effect of rhEPO on the need for blood transfusions and on hemoglobin (Hb) concentrations, 227 patients with… CONTINUE READING
BETA

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Similar Papers

Loading similar papers…